Premium
Twenty‐four‐hour intragastric acidity and clinical trial of bedtime enprostil 70 μg compared with ranitidine 300 mg in duodenal ulcer
Author(s) -
WALT R. P.,
POUNDER R. E.,
HAWKEY C. J.,
SANTANA I. A.,
SOMERVILLE K. W.,
LOGAN R. F. A.,
LONG R. G.,
LANGMAN M. J. S.
Publication year - 1987
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1987.tb00615.x
Subject(s) - bedtime , ranitidine , medicine , gastroenterology , duodenal ulcer , anesthesia
SUMMARY The effects of bedtime 70 μg and twice daily 35 μg doses of enprostil on 24‐hour intragastric acidity were investigated in nine duodenal ulcer patients in remission. Median nocturnal acidity decreased significantly by 30% with 35 μg twice daily, and by 48% with 70 μg at bedtime. In a clinical trial using bedtime dosing, 102 duodenal ulcer patients randomly received either ranitidine 300 mg or enprostil 70 μg. More ulcers healed after 4 and 8 weeks treatment with ranitidine than with enprostil (76% ranitidine vs 52% enprostil, at 4 weeks p = 0.0065 and 94% vs 68%, respectively at 8 weeks, P = 0.0007). However, 6 months after cessation of treatment there was no material difference in overall outcome. Despite combining mucosal protection with acid inhibition enprostil treatment conferred no advantage over simple acid inhibition.